Skip to content
type1.science
ObservationalNot yet recruitingNCT07739342

Abbott continuous glucose/ketone monitoring and DKA occurrence

Newly registered observational study of Abbott's investigational continuous dual glucose/ketone monitor in 1,200 adults and children with T1D. The study arm describes three months of sensor use while the primary DKA outcome is labelled over 12 months, an unresolved registry ambiguity.

Primary endpoints

  • Occurrence of diabetes-related ketoacidosis during 12 months

Results so far

No results posted. The study is expected to start in September 2026, enrol 1,200 participants in New Zealand, and complete in December 2027. The record describes three months of sensor exposure but gives the primary DKA outcome a 12-month time frame; the registry does not yet reconcile those durations.